Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018801 (heart failure)
 72,216 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Woman, 42 years-old, receiving immunosuppressive therapy for a lymphoma, presented reagudization of Chagas' disease, from its indeterminate phase. Intense inflammatory visceral aggression, due to extensive intracellular proliferation of the Trypanosoma cruzi, was the likely mechanism for acute myocarditis leading to severe right ventricular failure. Antiparasite chemotherapy was effective in the control of visceral involvement and for the remission of cardiac failure. The clinical course in this case is compatible with the hypothesis of early right ventricular damage in Chagas' disease.
 ...
PMID:[Reagudization of Chagas myocarditis inducing exclusive right ventricular failure]. 757 64

Aggressive methods of decreasing oxygen consumption, such as therapeutic musculoskeletal paralysis, are used in patients with marginal oxygen delivery associated with cardiac and respiratory insufficiency. This is especially true of new mechanical ventilation methods designed to decrease tidal volume and peak airway pressures. Agitation and delirium associated with brain failure also have become an important source of abnormally increased oxygen consumption in ICU patients. Hemodynamic deterioration from the effects of musculoskeletal hyperactivity can precipitate angina, heart failure, and cardiac arrhythmias by increasing myocardial work and oxygen consumption in the face of a fixed coronary artery output. Escalated doses of sedatives, followed by oppressive hemodynamic and ventilatory side-effects, sometimes indicate the need for therapeutic musculoskeletal paralysis to quickly control life-threatening agitation syndromes. Cerebral-function monitoring with portable, noninvasive, computer-processed monitors allows quick recognition of brain functions under titrated, suspended animation in real time, facilitating modulation of therapy when the visual clues of neuronal function disappear.
 ...
PMID:Neurologic monitoring in the intensive care unit. 792 25

The vein of Galen malformations continue to be challenging lesions for the neurosurgeon. Evolving therapies, including transvenous and transarterial embolotherapies, have dramatically changed our approach to these lesions over the past 5 years. The neurosurgeon remains the physician in charge of the care of these individuals. In neonates suffering from severe progressive cardiac failure, about a 50% survival rate can be expected. Those patients demonstrating significant injury to the central nervous system prior to therapy should probably be excluded from the aggressive treatment category. Low morbidity and mortality can be expected in the infant and older childhood group of patients harboring vein of Galen malformations treated interventionally. The tendency today is toward a combined transvenous transarterial approach to these lesions, no matter which clinical category is treated. Aggressive therapy is indicated in the control of hydrocephalus and seizures before, during, and after treatment. The overall philosophy, especially in the transvenous approach to these lesions, remains the careful and repeated embolization of these lesions in a staged fashion to encourage a graded thrombosis in an attempt to minimize the risk of hemorrhage and injury to the central nervous system. The overall prognosis is difficult to predict at this time, but it would appear to be better than with standard surgical treatment of these lesions. These therapies are evolving, and further improvements in the techniques and outcome are anticipated.
 ...
PMID:Vein of Galen fistulas. 808 4

Left ventricular assist devices (LVADs) driven by external sources and capable of sustaining life over weeks to months as a bridge to heart transplantation have been implanted in over 300 patients in the United States. Because of the limited availability of organs for transplantation, the remarkable degree to which LVADs reverse end-organ dysfunction, and patient acceptance, proposals for home LVAD treatment and for use of the LVAD as a permanent treatment for heart failure are being considered. LVAD therapy is associated with characteristic psychiatric and psychosocial problems, however, which must be addressed to optimize results. Among the first 30 LVAD patients treated at our center, psychiatric interventions were frequently required for family stress, major depression, organic mental syndromes, and serious adjustment disorders. Psychiatric problems most often occurred in patients with ongoing medical complications following LVAD implantation, and often significantly impaired rehabilitation. Both depression and organic mental syndromes were frequently associated with preexisting cerebrovascular disease, which was sometimes occult, and with strokes complicating LVAD therapy. Aggressive treatment of depression played a major role in improving functional status. LVADs may decompress heart transplant waiting lists and make it possible to optimize patients' physiological and functional status before transplantation. With increased LVAD use, however, neuropsychiatric factors can be expected to play a large role in determining quality of life and outcome both before and after heart transplantation.
 ...
PMID:Left ventricular assist devices. Psychosocial burden and implications for heart transplant programs. 893 21

The morbidity, mortality and health care costs associated with congestive heart failure make prevention a more attractive public health strategy than treatment. Aggressive management of etiologic factors, including hypertension, coronary artery disease, valvular disease and excessive alcohol intake, can prevent the left ventricular remodeling and dysfunction that lead to heart failure. Early intervention with angiotensin converting enzyme inhibitors in patients with chronic left ventricular dysfunction can prevent, as well as treat, the syndrome. Several intervention strategies in patients with acute myocardial infarction can slow or prevent the left ventricular remodeling process that antedates congestive heart failure. The primary care physician must be alert to the need for aggressive intervention to reduce the burden of heart failure syndrome on the patient and on society.
 ...
PMID:Preventing congestive heart failure. 957 27

Aggressive treatment of thoracic malignancy may be complicated by complex defects in the chest wall. These may be associated with serious complications such as chronic infection, respiratory or cardiac failure, or major haemorrhage. Closure of the defect and restoration of the integrity of the chest wall is important for both functional and cosmetic reasons. Local flaps are often used, but may be inadequate or unavailable. Reconstruction with free flaps is better in these cases, as this provides as much abundant well-vascularised tissue as is required. We present 12 patients treated successfully for complex chest wall defects using various forms of local and free flap reconstruction. There were five complications, three healed spontaneously and two required secondary procedures before they healed.
 ...
PMID:Closure of complex defects in the chest wall with muscle flaps. 978 28

The majority of patients with hypertension have one or more additional risk factors for cardiovascular disease. In planning an appropriate treatment program, it is useful to identify and stratify hypertensive patients according to their risk of developing cardiovascular, cerebrovascular, or renal disease. At particular risk are the elderly, patients with diabetes, and those with target-organ damage manifested by impaired renal function. Evidence supports increased risk in these patients, and clinical trial results demonstrate the considerable benefits realized through aggressive blood pressure (BP) control. The number of elderly individuals continues to increase in the United States and other industrialized countries. The prevalence of isolated systolic hypertension (ISH) is higher in the elderly than in younger individuals. ISH is associated with significant morbidity and mortality and should not be considered a physiologic manifestation of the normal aging process. Type 2 diabetes is also increasing in prevalence. Patients with diabetes are at increased risk for coronary heart disease, stroke, renal failure, and other cardiovascular complications. Aggressive treatment of elevated BP can produce dramatic decreases in the cardiovascular complications of diabetes. The incidence of end-stage renal disease has increased 2.5-fold in the past two decades, and poorly controlled BP is a major contributor to the increase. Lowering BP to levels well below the traditional goal of 140/90 mm Hg is needed to slow the progression of renal dysfunction and prevent renal failure in hypertensive patients with renal disease, whether related to diabetes or to another etiology. Aggressive treatment of hypertension in multiple-risk populations (to the goals of JNC VI and the recent WHO-ISH Guidelines for the Management of Hypertension) can be expected to produce significant reductions in the incidence and prevalence of stroke, heart failure, coronary heart disease, chronic renal failure, and total cardiovascular mortality.
 ...
PMID:Treating multiple-risk hypertensive populations. 1059 63

Hypertension is the leading preventable cause of premature morbidity and mortality from coronary heart disease, chronic heart failure, stroke and kidney failure. Despite the remarkable advances made in the design, development, and distribution of antihypertensive drugs and the plethora of published guidelines for hypertension treatment over the last two decades, blood pressure control rates remain rather disappointing. In the United States, Canada, and the United Kingdom, as well as in countries with far less resources devoted to health care, fewer than one in four hypertensives are controlled. This observation remains a major source of frustration for clinicians and health policy makers alike and serves as a constant reminder for more refined strategies for hypertension treatment and control. The 14th International Interdisciplinary Conference on Hypertension in Blacks (ISHIB99), held in Toronto, Canada on July 10-14, 1999 provided a unique forum for the discussion of this issue. The recommendations discussed are summarized herein under 10 specific headings that include: (1) Renewed emphasis on health education for patients and their families; (2) Increased involvement of non-physician health care providers; (3) Aggressive detection, evaluation and control of attendant cardiovascular risk factors; (4) Renewed determination for clinicians to set and achieve blood pressure targets; (5) Increased patient involvement in management decisions; (6) Improved access to quality care for the "working poor" and indigent; (7) Renewed commitment to community participation; (8) Partnership with managed care and professional organizations; (9) Renewed emphasis on the importance of psychosocial factors; (10) Enhanced communication and networking among hypertension care providers and between providers and patients.
 ...
PMID:Refining strategies for the prevention and control of hypertension and related complications. 1060 54

Clearly, sudden cardiac death syndrome in heart failure is linked to severely perturbed neurohumoral, hemodynamic, and mechanical systems. Routine antiarrhythmic drug therapy has not proven beneficial and, therefore, there is no justification for using these agents in unselected heart failure patients who are without significant symptomatic ventricular arrhythmia. Aggressive treatment of the failure syndrome seems most important. Because many of the problematic arrhythmias arise from triggering automaticity, which is known to occur in excessive ventricular stretch and wall stress, systemic vascular "unloading" with vasodilators and angiotensin-converting enzyme inhibitors is likely helpful. The most recent American College of Cardiology/American Heart Association Guidelines regarding therapeutic management of heart failure suggest that aggressive pharmacologic treatment of asymptomatic ventricular arrhythmias is best avoided. To be considered strongly for pharmacologic prescription or for implantation of a tachyarrhythmia termination device, a patient should have symptomatic ventricular tachycardia with an episode of syncope or sudden cardiac death syndrome rather than simply having palpitations of asymptomatic, unsustained ventricular tachycardia. Indeed, aggressively treating congestive heart failure with medication often eliminates potentially life-threatening arrhythmias. Appropriate use of vasodilators and, particularly, angiotensin-converting enzyme inhibitors is important. Correction of fluid balance and electrolyte disorders may be helpful to address symptoms and certainly is likely to decrease the potential for morbidity and mortality. On occasion it may be necessary to consider bradyarrhythmia pacemaker insertion or the use of atrioventricular nodal-ablation techniques with subsequent ventricular or atrioventricular pacer insertion. Obviously, sudden cardiac death due to sudden heart block or asystole might be attenuated with this strategy.
 ...
PMID:Sudden cardiac death syndrome and pump dysfunction: the link. 1101 84

Patients with heart failure do better if they are treated in a formal heart failure disease-management program than if they receive standard care: their hospitalization rates and costs of treatment are lower, and their functional status is higher. The programs feature close coordination between primary care givers, subspecialty consultants, and nurses with specialty training in the nuances of heart failure management. Aggressive medical therapy must be coupled with patient education and rapid response to early identified problems. This article reviews the principles of heart failure disease-management programs and cites evidence that they are beneficial.
 ...
PMID:Heart failure disease management: a team approach. 1120 66


<< Previous 1 2 3 4 5 6 7 8 9 Next >>